FindTrial
Sign In

Arm1

DRUG4 trials

Sponsors

Tata Memorial Hospital, Zydus Lifesciences Limited, Sun Yat-sen University, Prapokklao Hospital

Conditions

BRAFCRC (Colorectal Cancer)Carcinoma of Buccal MucosaHead and Neck CancersOral Squamous Cell CarcinomaTongue CancersUlcerative Colitisnursing practice guidelines for patients receiving High-Flow Nasal Cannula (HFNC) HFNC

Phase 2

Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study
NCT02748707
Tata Memorial HospitalCarcinoma of Buccal Mucosa, Head and Neck Cancers, Oral Squamous Cell Carcinoma +1
Start: 2015-08-18End: 2023-04-30Updated: 2022-04-28
A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates
CompletedNCT06398808
Zydus Lifesciences LimitedUlcerative Colitis
Start: 2024-04-08End: 2024-11-28Updated: 2024-12-20
Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer
Not yet recruitingNCT07714447
Sun Yat-sen UniversityBRAF, CRC (Colorectal Cancer)
Start: 2026-11-30End: 2029-02-26Target: 91Updated: 2026-07-21

Phase 3

Development of Nursing Practice Guidelines for Patients receiving high flow nasal cannula at Female Internal Medicine ward 2, Prapokklao Hospital
TCTR20260116001
Prapokklao Hospitalnursing practice guidelines for patients receiving High-Flow Nasal Cannula (HFNC) HFNC
Start: 2026-02-01Target: 30Updated: 2026-08-03

Related Papers

A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study.
Journal of Clinical Oncology2019-05-2010 citations